NCT00244816View on ClinicalTrials.gov

Taxoprexin® Treatment for Advanced Eye Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Metastatic Melanoma
Interventions
DRUG

Taxoprexin

Administered by intravenous infusion over 1 hour infusion for 5 consecutive weeks in a 6-weeks cycle.

Trial Locations (1)

77030-4009

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

American Regent, Inc.

INDUSTRY